[E-Daily] Heart Disease Diagnostic Medical Device Company AMCG Approved for New KONEX Listing

☞ Go to article

Trading immediately available, "KOSDAQ transfer listing within 2 years"

AMCG (CEO Seo Yong-sung), a heart disease diagnostic solution company using biomagnetic field measurement technology, was listed on KONEX on the 13th and announced this on the 16th. The Korea Exchange approved AMCG's new listing application submitted on November 20, and trading began immediately. The designated advisor for this listing is Daishin Securities.

Founded in 2021, AMCG has pursued commercialization after receiving Superconducting Quantum Interference Device (SQUID) technology and Magnetocardiography (MCG) system technology from the Korea Research Institute of Standards and Science (KRISS), a national standards agency. It is a company engaged in the heart disease diagnostic medical device business, having obtained item approvals from both domestic and US food and drug administrations.

The first released product 'MCG-S' is currently installed in two hospitals and is undergoing post-marketing phase clinical trials to "evaluate the accuracy of MCG Scan for patients suspected of coronary artery disease." It is focusing on obtaining new medical technology assessment in 2025 and health insurance coverage in 2026 through clinical results. The follow-up model, 'MCG-F', is being developed with lightweight technology, with the plan to obtain domestic item approval in 2025 and introduce it to the rapidly growing health check-up market.

Existing heart disease examination methods have limitations such as long time requirements and exposure to radiation risks due to the step-by-step application of stress electrocardiogram, echocardiography, cardiac nuclear medicine (SPECT) examination, and cardiac CT to obtain accurate results. AMCG's magnetocardiography scanner measures extremely tiny magnetic signals (one billionth of the Earth's magnetic field) from the myocardium using SQUID (Superconducting Quantum Interference Device), a next-generation quantum sensor, to provide diagnostic information, and is attracting attention as a next-generation heart disease diagnostic device.

CEO Seo said, "Despite the unfavorable venture investment conditions in 2024, we have attracted 10 billion won in investment and secured a total of 1.2 billion won in government contributions through Scale-up TIPS (R&D) projects, receiving recognition for our technology and business potential." He added, "The KONEX market listing will be an opportunity to grow as a global company in the field of early diagnosis of heart disease, with the goal of transferring to KOSDAQ within 2 years."

[E-Daily Reporter Lee Soon-yong]